

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (previously presented) An anti-allergic pharmaceutical composition containing at least two active agents chosen among :
(i) one allergen, (ii) one antihistamine compound, (iii) one inhibitor of histamine synthesis, said active agents being associated in said composition with a pharmaceutically acceptable vehicle.

Claim 2. (previously presented) The anti-allergic pharmaceutical composition according to claim 1, containing (i) at least one allergen and (ii) at least one antihistamine compound, and optionally (iii) at least one inhibitor of histamine synthesis, in a pharmaceutically acceptable vehicle.

Claim 3. (currently amended) The anti-allergic pharmaceutical composition according to any of claims 1 or 2 wherein said composition contains (i) at least one allergen and (ii) at least one antihistamine compound, in a pharmaceutically acceptable

vehicle, enabling release of the peptides and other chemical substances in independent manner ~~at galenic level~~.

Claim 4. (previously presented) A pharmaceutical composition according to any of claims 1 to 3, wherein the allergen is chosen from among the major antigens or mixture of major antigens of acarids able to induce an immune reaction.

Claim 5. (original) Pharmaceutical composition according to any of claims 1 to 4, characterized in that the allergen is a major antigen of *D. Pteronyssiinus* and/or *D. Farinae*.

Claim 6. (original) Pharmaceutical composition according to any of claims 1 to 5, characterized in that the allergen is a cystine protease.

Claim 7. (original) Pharmaceutical composition according to any of the preceding claims, characterized in that the allergen is at least a peptide epitope of a cystine protease.

Claim 8. (original) Pharmaceutical composition according to any of the preceding claims, characterized in that the allergen is at least a peptide epitope of a cystine protease whose amino

acid sequence is chosen from among SEQ ID NO : 1 and SEQ ID NO : 2 in the list of appended sequences.

Claim 9. (original) Pharmaceutical composition according to any of the preceding claims, characterized in that the allergen is a peptide or mixture of peptides chosen from the group comprising the peptides of sequences SEQ ID NO : 3, SEQ ID NO : 4, SEQ ID NO : 5 in the list of appended sequences.

Claim 10. (previously presented) The pharmaceutical composition according to any of claims 1 - 4, wherein the antihistamine compound is chosen from the group comprising: brompheniramine, cetirizine, fexofenadine, cyproheptadine, dexchlorpheniramine, hydroxyzine, ketotifene, loratidine, mequitazine, oxotomide, mizolastine, ebastine, astemizole, carbinoxamide, alimemazine, buclizine, cyclizine hydrochlorate, doxylamine.

Claim 11. (previously presented) The anti-allergic pharmaceutical composition according to any of claims 1 or 2, wherein said composition contains at least one antihistamine compound and at least one inhibitor of histamine synthesis, said compound being associated in said composition with a pharmaceutically acceptable vehicle.

Claim 12. (previously presented) The pharmaceutical composition according to claim 11, wherein the inhibitor of histamine synthesis is an inhibitor of histidine decarboxylase.

Claim 13. (previously presented) The pharmaceutical composition according to claim 12, wherein the inhibitor of histidine decarboxylase is tritoqualine.

Claim 14. (previously presented) The pharmaceutical composition according to any of claims 1 - 4 and 10, wherein said composition contains a quantity of allergen of the order of 1 to 1500 µg.

Claim 15. (previously presented) The pharmaceutical composition according to any of claims 1 - 4 and 10 - 14, wherein said composition contains a quantity of antihistamine compound of the order of 1 to 2000 mg.

Claim 16. (previously presented) The pharmaceutical composition according to any of claims 1 - 4 and 10 - 15, wherein said composition contains an inhibitor of histamine synthesis.

Claim 17. (previously presented) The pharmaceutical composition according to claim 16, wherein said composition contains a quantity of antihistamine compound of between 1 and 2000 mg.

Claim 18. (previously presented) The pharmaceutical composition according to any of claims 11 to 13, wherein said composition contains from 5 to 200 mg of an antihistamine compound and from 10 to 300 mg of an inhibitor of histidine decarboxylase.

Claim 19. (original) Pharmaceutical composition according to any of claims 1 to 10 or 14, characterized in that it comprises a nucleotide primer sequence SEQ ID NO : 6 in the list of appended sequences including an epigenic sequence of the major protein of the acarid, in lieu and stead of the composition containing the major protein of the acarid.

Claim 20. (original) Pharmaceutical composition according to any of claims 1 to 10 or 14 or 19, characterized in that it comprises a nucleotide primer sequence according to sequence SEQ ID NO : 6 in the list of appended sequences including an epigenic sequence of at least one epitope of the major allergen of the acarid in lieu and stead of the composition containing the major protein of the acarid.

Claim 21. (original) Pharmaceutical composition according to claim 20, characterized in that it comprises nucleotide primer sequences according to sequence SEQ ID NO : 6 in the list of appended sequences including in alternate manner at least two epigenic sequences of at least one epitope of the major allergen of the acarid in lieu and stead of the composition containing the major protein of the acarid.

Claim 22. (original) Pharmaceutical composition according to any of claims 1 to 10 or 14, characterized in that it comprises a nucleotide primer sequence SEQ ID NO : 7 in the list of appended sequences including an epigenic sequence of the major protein of the acarid, in lieu and stead of the composition containing the major protein of the acarid.

Claim 23. (original) Pharmaceutical composition according to any of claims 1 to 10 or 14 or 22, characterized in that it comprises a nucleotide primer sequence according to sequence SEQ ID NO : 7 in the list of appended sequences including an epigenic sequence of at least one epitope of the major allergen of the acarid in lieu and stead of the composition containing the major protein of the acarid.

Claim 24. (original) Pharmaceutical composition according to claim 23, characterized in that it comprises nucleotide primer sequences according to sequence SEQ ID NO : 7 in the list of appended sequences including in alternate manner at least two epigenic sequences of at least one epitope of the major allergen of the acarid in lieu and stead of the composition containing the major protein of the acarid.

Claim 25. (original) Pharmaceutical composition according to any of claims 1 to 10 or 14, characterized in that it comprises an RNA sequence enabling the coding of the major protein of the acarid in lieu and stead of the composition containing the major protein of the acarid.

Claim 26. (previously presented) The pharmaceutical composition according to any of claims 1 - 4 and 10 - 18, wherein said composition permits the TH2/TH1 switch and reduction of the allergic reaction both on the upstream phase (IgE synthesis) and on the downstream phase (synthesis and release of histamine).

Claim 27. (previously presented) The pharmaceutical composition according to any of claims 1 - 4, 10 - 18 and 26 wherein said composition is released in the form of a transcutaneous patch to

allow better access of the allergens used and/or their epitopes to the antigen-presenting cells.

Claim 28. (previously presented) The pharmaceutical composition according to any of claims 1 - 4, 10 - 18, 26 and 27, wherein said composition is released in mucosal, eye lotion, nasal spray or bronchial form.

Claim 29. (cancelled)

Claim 30. (previously presented) The pharmaceutical composition according to any of claims 1 - 4, 10 - 18 and 26 - 29 for the preparation of a medicinal product intended to treat or prevent allergic hypersensitive reactions.

Claim 31. (previously presented) The pharmaceutical composition according to any of claims 1 - 4, 10 - 18 and 26 - 30 for the preparation of a medicinal product intended to treat or prevent allergic asthma, allergic rhinitis, atopic and allergic eczema.

Claim 32. (previously presented) The pharmaceutical composition according to any of claims 1 - 4, 10 - 18 and 26 - 31 for the preparation of a medicinal product intended to treat or prevent allergic symptoms in children, infants and adults.

Claim 33. (previously presented) The pharmaceutical composition according to any of claims 1 - 4 and 10 wherein said composition contains a quantity of allergen of the order of 10 to 150 μ g.

Claim 34. (previously presented) The pharmaceutical composition according to any of claims 1 - 4 and 10 - 14, wherein said composition contains a quantity of antihistamine compound of the order of 5 to 200 mg.

Claim 35. (previously presented) The pharmaceutical composition according to claim 18, wherein said inhibitor of histidine decarboxylase is tritoqualine.